Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.

Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these […]